Skip to main content

Opaleye Management Inc.'s Form 4 filing

Eton Pharmaceuticals, Inc. (ETON) · filed Oct 8, 2024

Accession no.
0001493152-24-040490
Filed
Oct 8, 2024
Trade date
Oct 4-8, 2024
Filing delay
4 days
Rule 10b5-1 plan
Not checked

This filing lists 6 non-derivative transactions and 0 derivative transactions. Open-market purchases total $434.1K. It was filed 4 days after the trade.

Reporting owners

A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.

Reporting owners on this filing
OwnerRelationship to the company
Opaleye Management Inc.CIK 000159585510% Owner

Non-derivative securities (Table I)

Acquisitions and disposals of common stock and similar shares, one row per line on the filing.

Non-derivative transactions
Trade dateSecurityTransactionSharesPriceValueShares afterOwnershipFlags
Oct 4, 2024Common Stock, par value $0.001 per sharePPurchaseAcquired+15,000$6.77+$101,5502,720,000Indirect
Oct 4, 2024Common Stock, par value $0.001 per sharePPurchaseAcquired+1,852$6.77+$12,538.0476,852Indirect
Oct 7, 2024Common Stock, par value $0.001 per sharePPurchaseAcquired+10,000$7.22+$72,2002,730,000Indirect
Oct 7, 2024Common Stock, par value $0.001 per sharePPurchaseAcquired+1,248$7.22+$9,010.5678,100Indirect
Oct 8, 2024Common Stock, par value $0.001 per sharePPurchaseAcquired+30,000$7.03+$210,9002,760,000Indirect
Oct 8, 2024Common Stock, par value $0.001 per sharePPurchaseAcquired+3,970$7.03+$27,909.182,070Indirect

Footnotes

Livermore does not store Form 4 footnotes. For price ranges, how indirect holdings are held and trading plan details, read the original on SEC EDGAR.

Read the original on SEC EDGAR (opens in a new tab)